Indaptus Therapeutics, Inc. Common Stock (INDP) Stock
Key stats
- Market cap
- $427.71M
- Price / Earnings ratio
- -25.1x
- EPS (TTM)
- -$6.33
- Volume
- Loading
- 52-week high
- $5.96
- 52-week low
- $0.92
Source: third-party data provider, as of November 13, 2026
Compare with INDP
Recent news
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
INDP
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
INDP
Why Did INDP Stock Gain 12% Today?
Why Did INDP Stock Gain 12% Today?
INDPTechnical indicators
- RSI 14
- 53.50
- MACD 12/26/9
- 0.12
- EMA 9 of MACD
- 0.15
- MACD histogram
- -0.03
- SMA 50
- $2.88
- Price above SMA 50
- EMA 50
- $2.82
- Price above EMA 50
- SMA 200
- $2.31
- Price above SMA 200
- EMA 200
- $2.48
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
INDPMRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
INDPWhy Did INDP Stock Gain 12% Today?
Why Did INDP Stock Gain 12% Today?
INDPAbout Indaptus Therapeutics, Inc. Common Stock
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Junyi Dai | CEO & Chairman | 1987 |
| Mr. Yu Ding | Chief Financial Officer | 1975 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 53.50
- MACD 12/26/9
- 0.12
- EMA 9 of MACD
- 0.15
- MACD histogram
- -0.03
- SMA 50
- $2.88
- Price above SMA 50
- EMA 50
- $2.82
- Price above EMA 50
- SMA 200
- $2.31
- Price above SMA 200
- EMA 200
- $2.48
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +56.3 | -56.1 | -12.2 | +103.5 | +45.8 | -8.3 |
